Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remains a significant problem. Continuing advances in the refinement of dosing frequency protocols, as well as the development of therapies and devices that promise to extend dosing intervals, have the potential to overcome treatment burden, further enhancing long-term visual outcomes. In this podcast, Dr. Arshad Khanani and Dr. Nancy Holekamp discuss dosing schedules for emerging agents in the treatment of nAMD that require less frequent dosing than standard anti-VEGF therapies. Transcription: https://tinyurl.com/Ophthalmology3-3a For CME Credit, complete activity here: https://tinyurl.com/Ophth3-3a